BTAI (BioXcel Therapeutics) Float Percentage Of Total Shares Outstanding: 98.16% (As of Jul. 05, 2026)


BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $1.38
GF Value $0.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Float Percentage Of Total Shares Outstanding?

BioXcel Therapeutics BTAI 8 Float Percentage Of Total Shares Outstanding is 98.16% as of Jul. 05, 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioXcel Therapeutics's float shares is 30.31 Mil. BioXcel Therapeutics's total shares outstanding is 30.88 Mil. BioXcel Therapeutics's float percentage of total shares outstanding is 98.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioXcel Therapeutics's Insider Ownership is 1.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioXcel Therapeutics's Institutional Ownership is 18.57%.

BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioXcel Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=30.31/30.88
=98.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.16% mean?
BioXcel Therapeutics (BTAI) has a Float Percentage Of Total Shares Outstanding of 98.16% as of Jul. 05, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Float Percentage Of Total Shares Outstanding too high?
BioXcel Therapeutics' current Float Percentage Of Total Shares Outstanding is 98.16%. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Float Percentage Of Total Shares Outstanding compare to IXHL and SCYX?
BioXcel Therapeutics' Float Percentage Of Total Shares Outstanding of 98.16% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Float Percentage Of Total Shares Outstanding is 98.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.38 — trading 106% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.16%. BioXcel Therapeutics' overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Float Percentage Of Total Shares Outstanding is 98.16% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $1.38 is trading 106% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for BTAI:

  • Float Percentage Of Total Shares Outstanding: 98.16%
  • GF Value™: $0.67 vs. price of $1.38 (106% above fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$0.67
GF Value